Nectar, an allergy care platform, announced an $8 million seed round led by Juxtapose and Obvious Ventures, who are co-building the company alongside Founder and CEO Kenneth Chahine, Ph.D.
Nectar will be the consumer-facing brand of Nectar Life Sciences, an allergy-focused healthcare holding company led by Dr. Chahine. The Nectar platform will leverage data and clinical research to offer personalized allergy care aimed at treating the root cause of allergies and providing relief. Nectar’s differentiated model will provide consumers with convenience, flowing between virtual care and physical clinics. Read more.
